ClinicalTrials.gg
Active, not recruitingNCT05720910FRONEUpdated Nov 6, 2026

Streamlined Geriatric and Oncological Evaluation Based On IC Technology

An interventional study of GERONTE in Breast Cancer, Comorbidities and Coexisting Conditions and Lung Cancer, sponsored by Institut Bergonié. Active, not recruiting at 11 sites in France. Open to participants aged 70 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Institut Bergonié · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 6, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
70 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Breast Neoplasms by Institut Bergonié — 4 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Institut Bergonié.

Planned enrollment
3rd of 20
720 · median 87
Started
2024
the only one that year
No phase
16 of 29
3 open now
Registered
27th of 29
by date

Among the 29 studies in Breast Neoplasms by Institut Bergonié, this one is the 3rd largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2024, is one of 16 with no phase, and was the 27th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 29 studies in Breast Neoplasms by Institut Bergonié are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 70 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Breast Neoplasms by Institut Bergonié, or all of them as a file.
02

Study summary

The primary objective of GERONTE STUDY is to evaluate the effectiveness of the GERONTE, ICT-based, integrated care pathway to improve patient 6-month quality of life, in France.

Study design is a stepped wedge randomised controlled trial. Clusters will be participating hospitals, comprising eight investigating sites in total (Figure 2).

This is a stepped wedge of cross-over type. Patients included at each "step" are different individuals. The first "step" is a reference measurement where none of the clusters will implement the intervention. The investigating sites will be randomly drawn to determine the order in which they will implement the intervention, by "steps" of two months.

The primary endpoint is the Quality of Life assessed by the EORTC QLQ-C30 (version 3.0) questionnaire at 6 months after GERONTE implementation. It has 3 sub-scores that will be analysed independently, with alpha risk adjustment.

Read the detailed description

This is a stepped wedge of cross-over type. Patients included at each "step" are different individuals. The first "step" is a reference measurement where none of the clusters will implement the intervention. The investigating sites will be randomly drawn to determine the order in which they will implement the intervention, by "steps" of two months. A total of 10 patients by step are to be included in each center; these 10 patients must be regularly included along the 2-month period of each step. If 10 patients are already included before the end of the 2 months' step period, the center has to stop the inclusions till the beginning of the subsequent step. If a center, near to the end of a step, is far from reaching of the 10 patients' inclusion, it must increase the speed of its inclusions to be as close as possible of 10 patients included at the end of the step. In each center, patient sample has to be representative of type of cancer managed in the center, along the trial duration. The repartition of cancer types must be homogeneous along the steps and during the trial duration.

All participating investigating sites will have study collaborators in charge of organizing intervention implementation and data collection. The intervention will be prepared prior to the start of the trial, so that each investigating site can implement it as defined by the randomisation. Each center engaged to participate needs to participate till the end of the trial. A center commitment to participate will be requested before each center involvement to avoid center withdrawal after the start of the trial. Quantitative data regarding the myPatientSpace adapted for GERONTE app usage will be collected at each step and in each cluster by study collaborators, from the beginning of GERONTE system implementation. Care outcome data (Quality of life, anxiety, autonomy, additional hospitalisation, mortality...) will be collected by local referents at 3, 6, 9 and 12 months after inclusion in GERONTE. The data necessary to calculate the real cost of the intervention, of its implementation and of resource use data of patient management will be continuously collected during follow-up. GERONTE patient-centered system implementation and usage will be collected by the local referents in each center. Qualitative analysis will be performed in each center at GERONTE system implementation and during follow-up.

03

Conditions studied

  • Breast Cancer
  • Comorbidities and Coexisting Conditions
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
04

Who can participate

Ages eligible
70 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- General inclusion criteria

  1. Age ≥ 70 years old.
  2. New or progressive cancer (breast, lung, colorectal, prostate), proven or strong clinical suspicion, fulfilling the tumor specific criteria.
  3. Estimated greater than 6 months.
  4. At least one moderate/severe multimorbidity inclusion criteria other than current cancer (see separate list under 5.3).
  5. Patients must be willing and able to comply with study procedures.
  6. Voluntarily signed and dated written informed consents prior to any study specific procedure.
  7. QLQ-C30 Quality of Life Questionnaire fully completed at baseline, before inclusion.
  8. Patients affiliated with a French social security scheme in accordance with the French law on biomedical research (Article 1121-11 of the French Code of Public health).

    Tumor specific inclusion criteria

  9. Specific inclusion criteria for breast cancer:

    9.1. Non- breast cancer (M0):

    - No prior treatment for the current breast cancer.

    - All 3 criteria required:

    o Clinical staging: cT2-3-4 Nany, or cTany N1-2-3;

    • The cancer specialist considers* surgery;
    • The cancer specialist considers* radiotherapy and/or chemotherapy. 9.2. Metastatic breast cancer (M1): Both criteria required:

      • The cancer specialist considers* chemotherapy or PARP-inhibitors or mTOR-inhibitors / PIK3CA inhibitors; Previous endocrine therapy +/- CDK4/6 inhibitors is allowed;
      • The patient received maximum 1 for metastatic disease.

        • 'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.
  10. Specific inclusion criteria for colorectal cancer:

    10.1. Non-metastatic colorectal cancer (M0):

    - No prior therapy for the current tumor in the recruiting hospital

    • At least one of the 3 criteria required:

      o The cancer specialist considers* surgery;

      • The cancer specialist considers* radiotherapy;
      • The cancer specialist considers* chemotherapy and/or immunotherapy. 10.2. Metastatic colorectal cancer (M1):
    • The cancer specialist considers* first or second line systemic therapy and/or radiotherapy (+/- surgery). No previous chemotherapy allowed except /perioperative chemotherapy stopped for more than 12 months.

      • 'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.
  11. Specific inclusion criteria for lung cancer:

11.1. Non-metastatic lung cancer (M0):

  • No prior therapy for the current tumor in the recruiting hospital
  • At least one of the 3 criteria required:

    • The cancer specialist considers* surgery (patients considered for treatment with percutaneous thermoablation alone are not eligible);
    • The cancer specialist considers* radiotherapy (except SBRT);
    • The cancer specialist considers* systemic therapy. Possible systemic therapies are chemotherapy and/or immune therapy and/or targeted therapy. Patients only considered* for monotherapy with anti-EGFR TKI or somatostatin analog are not eligible.

11.2. Metastatic lung cancer (M1):

  • The cancer specialist considers* first or second line systemic therapy. Possible systemic therapies are chemotherapy and/or immune therapy and/or targeted therapy. Patients only considered* for monotherapy with anti-EGFR TKI or somatostatin analog are not eligible.

    *'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.

    12. Specific inclusion criteria for prostate cancer: 12.1. Non-metastatic prostate cancer (M0): one of the following:

  • First diagnosis M0 prostate cancer (no therapy received yet for prostate cancer): at least one of the 2 criteria required:

    o The cancer specialist considers* radiotherapy;

    o The cancer specialist considers* hormone therapy (ADT +/- combination Abiraterone and Prednisone).

  • Salvage treatment M0 prostate cancer (received prior surgery at least 6 months before):

    o The cancer specialist considers* radiotherapy (+/- ADT)

  • Non-metastatic castration resistant prostate cancer:

    • The cancer specialist considers* treatment intensification (ADT + Enzalutamide or Apalutamide or Darolutamide).

12.2. Metastatic prostate cancer (M1): - The cancer specialist considers* treatment with Abiraterone or Enzalutamide or Apalutamide, or Docetaxel or Cabazitaxel or PARP-inhibitors or Lutetium PSMA.

*'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.

Exclusion criteria

Exclusion Criteria:

  1. Mental illness/cognitive impairment that limits ability to provide consent or complete trial procedures.
  2. Participating to an interventional clinical trial with a non-registered anticancer drug or to another geriatric intervention trial.
  3. Patients and caregivers are unable or unwilling to use ICT-devices (tablet,computer, smartphone) or the Internet according to protocol.
  4. Patient already included in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
720 participants (estimated)

Study arms

  • Experimental
    GERONTE

    The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway;

    Other: GERONTE

  • No intervention
    CONTROL ARM

    Patients included in the control arm will be managed according to the standard of care.

Interventions

  • OtherGERONTE

    The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway

06

What researchers measure

Primary outcomes

  1. Quality of life assessed by the EORTC quality of life questionnaire (EORTC QLQ-C30 )

    Quality of life assessed by the quality of life questionnaire (EORTC QLQ-C30) questionnaire at 6 months after inclusion: * Normalised global health status score * Normalised score of the physical functioning scale * Normalised score of the emotional functioning scale the minimum value of the EORTC QLQ-C30 is 30 and the maximum value is 126, and higher scores mean a worse result.

    Time frame: 6 months

Secondary outcomes

  1. Quality of life of elders cancer patients

    Scores of the quality of life questionnaire for elderly cancer patients.(QLQ-ELD14). The minimum value is 14 and the maximum value is 40, and higher scores mean a worse result.

    Time frame: baseline 3, 9 and 12 months

  2. Quality of life by the EORTC quality of life questionnaire (EORTC QLQ-C30 )

    The quality of life questionnaire (QLQ-C30) scores. The minimum value of the EORTC QLQ-C30 is 30 and the maximum value is 126, and higher scores mean a worse result.

    Time frame: baseline 3, 9 and 12 months

  3. Survival

    Overall survival and progression-free survival

    Time frame: at 12 months

  4. Patient frailty

    Score of the Clinical frailty scale

    Time frame: baseline, 3, 6, 9 and 12 months

  5. Patient autonomy,

    Dependence score of the Activities of Daily Living scale (ADL); Proportion of patients living at home; Number of completed chair stands in 30 seconds

    Time frame: baseline, 3, 6, 9 and 12 months

  6. Patient weight evolution

    Weight in Kilograms

    Time frame: baseline, 3, 6, 9 and 12 months

  7. Patient anxiety

    Score of Hospital Anxiety and Depression (HAD) scale. The minimum value is 0 and the maximum value is 21, and higher scores mean a worse result.

    Time frame: baseline, 3, 6, 9 and 12 months

  8. institutionalisation

    Proportion of patient institutionalised per participants

    Time frame: 6 and 12 months

  9. unscheduled hospitalisations

    Proportion of unscheduled hospitalisations per participants

    Time frame: 6 and 12 months

  10. Cost per life years gained

    using utility assessed through normalised scores of EQ-5D-5L questionnaire

    Time frame: baseline, 3, 6, 9 and 12 months

  11. Caregiver burden in health, psychological well-being, finances, social life and relationship with patient

    Zarit Burden Interview

    Time frame: baseline, 3, 6, 9 and 12 months

  12. Patient experience of person-centered coordinated care

    Person-Centered Coordinated Care Experience Questionnaire (P3CEQ)The minimum value is 0 and the maximum value is 45, and higher scores mean a better result.

    Time frame: 6 and 12 months

  13. Patient, physician and health-professionals-reported overall satisfaction with the IC technology of the GERONTE system

    Score derived from the mHealth App Usability Questionnaire (MAUQ) for standalone mHealth Apps using the Patient version for patient satisfaction and the provider version for physician and health-professional.The minimum value is 0 and the maximum value is 126, and higher scores mean a better result.

    Time frame: 6 and 12 months

  14. GERONTE patient-centered system implementation and usage

    use of the myPatientSpace adapted for GERONTE app measures, for instance: number and frequency of connections.

    Time frame: 6 months

07

Study locations

11 sites
08

References and documents

Publications

  • Hamaker ME, Wildiers H, Ardito V, Arsandaux J, Barthod-Malat A, Davies P, Degol L, Ferrara L, Fourrier C, Kenis C, Kret M, Lalet C, Pelissier SM, O'Hanlon S, Rostoft S, Seghers N, Saillour-Glenisson F, Staines A, Schwimmer C, Thevenet V, Wallet C, Soubeyran P. Study protocol for two stepped-wedge interventional trials evaluating the effects of holistic information technology-based patient-oriented management in older multimorbid patients with cancer: The GERONTE trials. J Geriatr Oncol. 2024 May;15(4):101761. doi: 10.1016/j.jgo.2024.101761. Epub 2024 Apr 5. PubMed 38581958 ↗
09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Nov 2026, 24 months.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 24 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2023
First posted
Feb 9, 2023
StartActual
Oct 15, 2024
Primary completionActual
Nov 5, 2026was Oct 2026
CompletionEst.
Apr 14, 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Nov 5, 2026 (actual)
Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    Primary completion Oct 2026→Nov 5, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 13, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05720910
Lead sponsor
Institut Bergonié
Collaborators
EUCLID Clinical Trial Platform, University of Bordeaux
Responsible party
Sponsor
First posted
Feb 9, 2023
Start date
Oct 15, 2024
Primary completion
Nov 5, 2026
Completion
Apr 14, 2027 (estimated)
Last update
Nov 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion